Melatonin Pathway and Atenolol-Related Glucose Dysregulation: Is There a Correlation?

Clinical and Translational Science

Volumn 9, Issue 2, 2016, Pages 114-122

  Chang, Sw ^a   Gong, Y ^a   Mcdonough, Cw ^a   Langaee, Ty ^a   Nasiri Kenari, N ^a   Beitelshees, Al ^b   Gums, Jg ^c   Chapman, Ab ^d   Turner, St ^e   Johnson, Ja ^a,c   Cooper Dehoff, Rm ^a,c  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; ATENOLOL; CREATININE; GLUCOSE; HYDROCHLOROTHIAZIDE; MELATONIN; 6-SULFATOXYMELATONIN; GLUCOSE BLOOD LEVEL; PROTEIN KINASE C BETA;

ADULT; AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE URINE LEVEL; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE LINEAR REGRESSION ANALYSIS; PHARMACOGENETICS; PRIORITY JOURNAL; PRKCB GENE; PROTEIN URINE LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DIET RESTRICTION; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; URINE;

ATENOLOL; BLOOD GLUCOSE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FASTING; FEMALE; GLUCOSE; HUMANS; MALE; MELATONIN; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASE C BETA; SIGNAL TRANSDUCTION;

EID: 84960158104     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12389     Document Type: Article

References (50)

1. Axelrod, J. The pineal gland: a neurochemical transducer. Science 184, 1341-1348 (1974).
2. Little, K.Y., Kirkman, J.A. & Duncan, G.E. Beta-adrenergic receptor subtypes in human pineal gland. J. Pineal Res. 20, 15-20 (1996).
3. Peschke, E., Bahr, I. & Muhlbauer, E. Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. Int. J. Mol. Sci. 14, 6981-7015 (2013).
4. McMullan, C.J., Schernhammer, E.S., Rimm, E.B., Hu, F.B. & Forman, J.P. Melatonin secretion and the incidence of type 2 diabetes. JAMA 309, 1388-1396 (2013).
5. McMullan, C.J., Curhan, G.C., Schernhammer, E.S. & Forman, J.P. Association of nocturnal melatonin secretion with insulin resistance in nondiabetic young women. Am. J. Epidemiol. 178, 231-238 (2013).
6. Kawakami, N., Takatsuka, N. & Shimizu, H. Sleep disturbance and onset of type 2 diabetes. Diabetes Care 27, 282-3 (2004).
7. Scheer, F.A., Hilton, M.F., Mantzoros, C.S. & Shea, S.A. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc. Natl. Acad. Sci. USA. 106, 4453-4458 (2009).
8. Leproult, R., Holmback, U. & Van Cauter, E. Circadian misalignment augments markers of insulin resistance and inflammation, independently of sleep loss. Diabetes 63, 1860-1869 (2014).
9. Bouatia-Naji, N. et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat. Genet. 41, 89-94 (2009).
10. Prokopenko, I. et al. Variants in MTNR1B influence fasting glucose levels. Nat. Genet. 41, 77-81 (2009).
11. Lyssenko, V. et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat. Genet. 41, 82-88 (2009).
12. Gupta, A.K. et al. Determinants of new-onset diabetes among 19, 257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 31, 982-988 (2008).
13. Cooper-Dehoff, R. et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am. J. Cardiol. 98, 890-4 (2006).
14. Elliott, W.J. & Meyer, P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369, 201-207 (2007).
15. Vaughan, G.M. et al. Nocturnal elevation of plasma melatonin and urinary 5-hydroxyindoleacetic acid in young men: attempts at modification by brief changes in environmental lighting and sleep and by autonomic drugs. J. Clin. Endocrinol. Metab. 42, 752-764 (1976).
16. Stoschitzky, K. et al. Influence of beta-blockers on melatonin release. Eur. J. Clin. Pharmacol. 55, 111-115 (1999).
17. Brismar, K., Hylander, B., Eliasson, K., Rossner, S. & Wetterberg, L. Melatonin secretion related to side-effects of beta-blockers from the central nervous system. Acta Med. Scand. 223, 525-530 (1988).
18. Cowen, P.J., Fraser, S., Sammons, R. & Green, A.R. Atenolol reduces plasma melatonin concentration in man. Br. J. Clin. Pharmacol. 15, 579-581 (1983).
19. Nathan, P.J., Maguire, K.P., Burrows, G.D. & Norman, T.R. The effect of atenolol, a beta1-adrenergic antagonist, on nocturnal plasma melatonin secretion: evidence for a dose-response relationship in humans. J. Pineal Res. 23, 131-135 (1997).
20. Johnson, J.A. et al. Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am. Heart J. 157, 442-449 (2009).
21. Graham, C., Cook, M.R., Kavet, R., Sastre, A. & Smith, D.K. Prediction of nocturnal plasma melatonin from morning urinary measures. J. Pineal Res. 24, 230-238 (1998).
22. Nowak, R., McMillen, I.C., Redman, J. & Short, R.V. The correlation between serum and salivary melatonin concentrations and urinary 6-hydroxymelatonin sulphate excretion rates: two non-invasive techniques for monitoring human circadian rhythmicity. Clin. Endocrinol. (Oxf.). 27, 445-452 (1987).
23. BÜHLMANN. BÜHLMANN 6-Sulfatoxymelatonin ELISA. https://www.alpco.com/pdfs/01/01-EK-M6S.pdf:; 2011.
24. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559-575 (2007).
25. Price, A.L., Patterson, N.J., Plenge, R.M., Weinblatt, M.E., Shadick, N.A. & Reich, D. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38, 904-909 (2006).
26. Reiter, R.J. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev. 12, 151-80 (1991).
27. Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27-30 (2000).
28. Kanehisa, M. et al. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 42, D199-205 (2014).
29. Gong, Y. et al. PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment. Pharmacotherapy 34, 123-130 (2014).
30. Aberg, H., Morlin, C. & Lithell, H. Different long-term metabolic effects of enalapril and atenolol in patients with mild hypertension. EGTA Group. J. Hum. Hypertens. 9, 149-153 (1995).
31. Helgeland, A., Strommen, R., Hagelund, C.H. & Tretli, S. Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway. Lancet 1, 872-875 (1986).
32. Peschke, E. Melatonin, endocrine pancreas and diabetes. J. Pineal Res. 44, 26-40 (2008).
33. Nishida, S., Segawa, T., Murai, I. & Nakagawa, S. Long-term melatonin administration reduces hyperinsulinemia and improves the altered fatty-acid compositions in type 2 diabetic rats via the restoration of Delta-5 desaturase activity. J. Pineal Res. 32, 26-33 (2002).
34. Sartori, C. et al. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology 150, 5311-5317 (2009).
35. Zanuto, R. et al. Melatonin improves insulin sensitivity independently of weight loss in old obese rats. J. Pineal Res. 55, 156-165 (2013).
36. Sarafidis, P.A. & Bakris, G.L. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 99, 431-436 (2006).
37. Barzilay, J.I., Davis, B.R. & Whelton, P.K. The glycemic effects of antihypertensive medications. Curr. Hypertens. Rep. 16, 410 (2014).
38. Kawakami, T., Kawakami, Y. & Kitaura, J. Protein kinase C beta (PKC beta): normal functions and diseases. J. Biochem. 132, 677-682 (2002).
39. Bonnefond, A. et al. Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat. Genet. 44, 297-301 (2012).
40. Peschke, E. et al. Melatonin and type 2 diabetes - a possible link? J. Pineal Res. 42, 350-358 (2007).
41. Tabit, C.E. et al. Protein kinase C-beta contributes to impaired endothelial insulin signaling in humans with diabetes mellitus. Circulation 127, 86-95 (2013).
42. Osterhoff, M.A. et al. Identification of a functional protein kinase Cbeta promoter polymorphism in humans related to insulin resistance. Mol. Genet. Metab. 93, 210-215 (2008).
43. Ward, L.D. & Kellis, M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 40, D930-D934 (2012).
44. Nichols, G.A., Hillier, T.A. & Brown, J.B. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. Am. J. Med. 121, 519-524 (2008).
45. Jansson, S.P., Svardsudd, K. & Andersson, D.K. Effects of fasting blood glucose levels and blood pressure and treatment of diabetes and hypertension on the incidence of cardiovascular disease: a study of 740 patients with incident Type 2 diabetes with up to 30 years' follow-up. Diabet. Med. 31, 1055-1063 (2014).
46. Sung, J., Song, Y.M., Ebrahim, S. & Lawlor, D.A. Fasting blood glucose and the risk of stroke and myocardial infarction. Circulation 119, 812-819 (2009).
47. Stacey, R.B., Leaverton, P.E., Schocken, D.D., Peregoy, J.A. & Bertoni, A.G. Prediabetes and the association with unrecognized myocardial infarction in the multi-ethnic study of atherosclerosis. Am. Heart J. 170, 923-928 (2015).
48. The Use of Medicines in the United States: Review of 2011: IMS Institute for Healthcare Informatics 2012.
49. Health, United States, 2013: With Special Feature on Prescription Drugs: National Center for Health Statistics 2014.
50. Tirosh, A. et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. N. Engl. J. Med. 353, 1454-1462 (2005).